{"name":"InteKrin Therapeutics, Inc.","slug":"intekrin-therapeutics-inc","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"INT131 besylate","genericName":"INT131 besylate","slug":"int131-besylate","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"INT131 besylate","genericName":"INT131 besylate","slug":"int131-besylate","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiR0FVX3lxTFBBN2hBNmZDNW5tX3Rxb1JMM2hYb0ZsWHJIUHY0aE43aVI1cnJVY1djTHJKRjN0b3FBSHJYTWs0MXhXTGdxRmxj?oc=5","date":"2022-04-06","type":"pipeline","source":"moneyinc.com","summary":"10 Things You Didn’t Know About Eric Easom - moneyinc.com","headline":"10 Things You Didn’t Know About Eric Easom","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}